Skip to main content

Narcolepsy With Cataplexy

1
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

NLS Pharmaceutics
NLS PharmaceuticsSwitzerland - Zurich
1 program
1
MazindolPhase 21 trial
Active Trials
NCT05055024Completed52Est. Jan 2023
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
2 programs
JZP-258PHASE_31 trial
XyremPHASE_31 trial
Active Trials
NCT03030599Completed201Est. Jul 2019
NCT02221869Completed106Est. Jan 2019
UCB Pharma
UCB PharmaBelgium - Brussels
1 program
Sodium OxybatePHASE_11 trial
Active Trials
NCT00345800Completed25Est. Jan 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Jazz PharmaceuticalsJZP-258
Jazz PharmaceuticalsXyrem
NLS PharmaceuticsMazindol
UCB PharmaSodium Oxybate

Clinical Trials (4)

Total enrollment: 384 patients across 4 trials

A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy

Start: Mar 2017Est. completion: Jul 2019201 patients
Phase 3Completed

A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy

Start: Oct 2014Est. completion: Jan 2019106 patients
Phase 3Completed

An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy

Start: Oct 2021Est. completion: Jan 202352 patients
Phase 2Completed
NCT00345800UCB PharmaSodium Oxybate

Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes

Start: Apr 2006Est. completion: Jan 200825 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.